Third generation: multi-receptor agonists Tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, producing greater metabolic effects than GLP-1 alone: Mounjaro , once-weekly injection for type 2 diabetes (FDA-approved 2022)
You cannot manage what you do not measure
Compared with the other medications, people taking the GLP-1 drugs had a reduced risk for addiction: 18% for alcohol, 14% for cannabis, 20% for both cocaine and nicotine, and 25% for opioids
Patients taking other medications, especially those that also affect the central nervous system, should provide their healthcare provider with a complete list of their current medications
and (4) has excellent universality for various lipid carriers and can be extended to other forms of active targeting mediated by transmembrane receptors